And their plan is simple. Finalize the 2B trial in April, report on the results by September, and either partner with big pharma, or preferably sell the company to big pharma in the 4th quarter.
Other pertinent info is that they believe the market for the drug for SPMS is $7 billion+. There is no current drug on the market for that condition.
A number I researched that is an average multiple for the sale of small biotechs is 4, therefore if it was agreed that sales for the product annually would be $1 billion, the company would sell for $4 billion, as I understand it.
If the current options available are exercised there will be just under 250,000,000 shares outstanding at that point.
I can't tell you that what I've written here is positively, absolutely right, but it is what I've found with my research.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM